Simultaneous determination of mecamylamine, nicotine, and cotinine in plasma by gas chromatography-mass spectrometry.
The nicotine receptor antagonist mecamylamine has been shown to increase the efficacy of transdermal nicotine as a pharmacotherapy for tobacco addiction. A product for simultaneous transdermal administration of nicotine and mecamylamine is undergoing clinical trials. In order to carry out pharmacokinetic studies, quantitation of low nanogram per milliliter levels of mecamylamine and nicotine was required. This paper describes a method for simultaneous determination of mecamylamine, nicotine, and the nicotine metabolite, cotinine, in human plasma using gas chromatography-mass spectrometry (GC-MS). Limits of quantitation for mecamylamine, nicotine and cotinine are 2, 1 and 2 ng/ml, respectively.
Jacob
P
P
Department of Medicine and Drug Dependence Research Center, Langley Porter Psychiatric Institute, University of California, San Francisco 94110, USA. peyton@itsa.ucsf.edu
Wu
S
S
Yu
L
L
Benowitz
N L
NL
D003367:Cotinine / Q000097:blood*; D008401:Gas Chromatography-Mass Spectrometry; D006801:Humans; D007202:Indicators and Reagents; D008464:Mecamylamine / Q000097:blood* / Q000493:pharmacokinetics; D009538:Nicotine / Q000097:blood*; D018722:Nicotinic Agonists / Q000097:blood*; D018733:Nicotinic Antagonists / Q000097:blood* / Q000493:pharmacokinetics; D012015:Reference Standards; D015203:Reproducibility of Results; D012996:Solutions
D007202:Indicators and Reagents; D018722:Nicotinic Agonists; D018733:Nicotinic Antagonists; D012996:Solutions; D008464:Mecamylamine; D009538:Nicotine; D003367:Cotinine